Sukh Chopra
Co-founder & ED (Biotech CDMO-CGT)
SGVector Pte Ltd
The startup develops viral vectors for the production and manufacturing of cell and gene therapies targeting rare genetic disorders and autoimmune diseases. By providing these vectors, the company enhances therapeutic options for patients and healthcare providers, facilitating more effective treatment pathways.
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
The cell and gene therapy (CGT) field faces challenges in viral vector manufacturing, including scalability, high costs, and the need for customized solutions. These challenges hinder the accessibility and innovation of CGTs, limiting their potential impact on treating genetic disorders and other diseases.
Solution
SGVector offers viral vector development and manufacturing services to enhance the accessibility and innovation of cell and gene therapies. Utilizing a suspension-based HEK293 system, SGVector provides scalable and efficient viral vector production across multiple serotypes and variants. The company performs developability and manufacturability assessments to mitigate risks during scale-up, while also developing in-house release tests to monitor critical quality attributes. SGVector's capabilities span vector design and development, process development, scale-up, production, and analytical testing, offering flexibility with multiple production methods to meet specific client needs.
Target Audience
SGVector serves pharmaceutical companies, biotechnology firms, academic researchers, and clinicians involved in cell and gene therapy development.
Features
- Suspension-based HEK293 platform for scalable viral vector production
- Vector design and development, including Rep-Cap helper and transfer plasmids
- Process development, scale-up, and optimization from small to large scale
- Assay development and analytical testing for quality, purity, and potency
- Developability and manufacturability assessments to address potential risks
- In-house release tests for monitoring critical quality attributes
- Capability to produce AAV and Lentiviral vectors
- Upstream and downstream process development